A Phase 1 Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of Escalating Doses Of A Vaccine-based Immunotherapy Regimen (Vbir) For Prostate Cancer (Pf-06753512)
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2017
At a glance
- Drugs PF 6753512 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 09 Aug 2017 Status changed from suspended to recruiting.
- 22 May 2017 Planned number of patients changed from 108 to 133.
- 22 May 2017 Status changed from recruiting to suspended.